Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresh Off Schering-Plough Deal, Huya Signs Pact With Beijing Institute To Open Bridge To Global Markets

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Huya Bioscience International has signed a partnership agreement with the Beijing Institute of Materia Medica on joint development of innovative drugs that ultimately could help the institute penetrate the American and European markets, according to a senior Huya executive

You may also be interested in...



San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development

BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development

San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development

BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development

China On The Road Toward Becoming World Center For Drug Innovation, Say Huya Bioscience Leaders

BEIJING - The science-savvy leaders of China, along with the Western-educated Chinese chemists and biologists migrating back here, are helping lay the foundation for the country one day to become a world center for innovation in developing new-generation medicines, according to senior executives at the San Diego-headquartered Huya Bioscience

Related Content

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel